Alzheimer’s and Parkinson’s pipelines are rapidly expanding beyond amyloid and into next-generation mechanisms such as α-synuclein, neuroinflammation, and metabolic targets. Against the backdrop of a globally surging patient population, the urgency for more effective, disease-modifying interventions has never been greater.

In its 14th year, the Alzheimer’s and Parkinson’s Drug Development Summit is committed to spotlighting the latest trailblazing innovation, from novel interventions for disease modification, encompassing protein aggregation, neuroinflammation, metabolic pathways, neurotrophic factors and more to the groundbreaking progress in p-tau217 and fluid-based biomarkers.

The 2026 program is built to explore disease progression, modification and prodromal intervention, so the next generation of therapeutics can prevent as well provide a meaningful impact to neurodegenerative patients in need.

What can you expect?

• 2 deep dive workshops into in vivo and in vitro modelling advancements
• Seminar day on fluid-based biomarker innovation
• 30+ expert speakers including industry leaders, academic KOLs and patient voices
• Multiple tracks of content spanning discovery, preclinical, clinical and regulatory
• 10+ hours dedicated networking time over 3 days

Don’t miss your opportunity to connect with leading drug developers and discover next-generation therapeutics redefining neurodegenerative treatment.

Find out more here – https://ter.li/ybtrdq